Atossa Therapeutics (ATOS) Enterprise Value (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Enterprise Value of -$31.7 million for Q1 2026, up 51.32% year-over-year from -$20.9 million in Q1 2025, and down 28718.18% quarter-over-quarter from -$110000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Enterprise Value (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Enterprise Value for 16 consecutive years, with -$31.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 51.32% year-over-year to -$31.7 million; the TTM figure through Mar 2026 stood at -$31.7 million (up 51.32% YoY), while the FY2025 annual figure was -$110000.0, up 99.85% from the prior year.
- Enterprise Value eased to -$31.7 million in Q1 2026 per ATOS's latest filing, from -$110000.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$110000.0 in Q4 2025 and bottomed at -$131.5 million in Q1 2022.
- Historically, Enterprise Value has averaged -$81.6 million across 5 years, with a median of -$84.0 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 100709.09% — and 2025, when it jumped 99.85%.
- Atossa Therapeutics' Enterprise Value stood at -$110.9 million in 2022, then rose by 20.23% to -$88.5 million in 2023, then climbed by 19.64% to -$71.1 million in 2024, then surged by 99.85% to -$110000.0 in 2025, then tumbled by 28718.18% to -$31.7 million in 2026.
- Business Quant data shows ATOS's Enterprise Value at -$31.7 million in Q1 2026, -$110000.0 in Q4 2025, and -$51.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | Atossa Therapeutics | 22.79 Mn | 22.79 Mn | - | -26.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.10 Mn |
| Mar 31, 2026 | -31.70 Mn |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | -51.85 Mn |
| Jun 30, 2025 | -57.90 Mn |
| Mar 31, 2025 | -65.12 Mn |
| Dec 31, 2024 | -71.08 Mn |
| Sep 30, 2024 | -74.77 Mn |
| Jun 30, 2024 | -79.53 Mn |
| Mar 31, 2024 | -83.96 Mn |
| Dec 31, 2023 | -88.46 Mn |
| Sep 30, 2023 | -94.03 Mn |
| Jun 30, 2023 | -99.39 Mn |
| Mar 31, 2023 | -103.87 Mn |
| Dec 31, 2022 | -110.89 Mn |
| Sep 30, 2022 | -117.37 Mn |
| Jun 30, 2022 | -125.54 Mn |
| Mar 31, 2022 | -131.49 Mn |
| Dec 31, 2021 | -110,000.00 |
| Sep 30, 2021 | -140.04 Mn |